retatrutide type 2 diabetes ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Overall impressive retatrutide TRANSCEND-T2D-1 studied

2018;378(25):e34

Week 9 and beyond: Reach the target maintenance dose, which is personalized depending on treatment goals and patient response

So if youre feeling like youve plateaued, your body weight isnt moving as much as you hoped, or you want a next step in terms of what might help improve your metabolic health and weight management, switching could be a logical conversation

Exercise timing considerations Many users prefer not to exercise on injection day due to potential nausea and discomfort

I couldn't be happier with the success Ive had with Ro by my side

However, the cross-sectional design and the limited effect sizes call for cautious interpretation